APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiation Injury Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radiation Injury Drugs Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchRadiation Injury Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiation Injury Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Radiation Injury Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiation Injury Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiation Injury Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Radiation Injury Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radiation Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiation Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiation Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radiation Injury Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radiation Injury Drugs market include Windtree Therapeutics Inc, Tonix Pharmaceuticals Holding Corp, Synedgen Inc, PharmaIN Corp and FirstString Research Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Radiation Injury Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiation Injury Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiation Injury Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiation Injury Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Radiation Injury Drugs Segment by Company

Windtree Therapeutics Inc

Tonix Pharmaceuticals Holding Corp

Synedgen Inc

PharmaIN Corp

FirstString Research Inc

Radiation Injury Drugs Segment by Type

DG-3

Des-Asp Angiotensin 1

C-2E5

C-2E2

BMX-001

Aerosurf

Others

Radiation Injury Drugs Segment by Application

Hospital

Clinic

ASCs

Others

Radiation Injury Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Radiation Injury Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Radiation Injury Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiation Injury Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Radiation Injury Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiation Injury Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiation Injury Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiation Injury Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiation Injury Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiation Injury Drugs industry.

Chapter 3: Detailed analysis of Radiation Injury Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Radiation Injury Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Radiation Injury Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiation Injury Drugs Industry Trends Table 2. Radiation Injury Drugs Industry Drivers Table 3. Radiation Injury Drugs Industry Opportunities and Challenges Table 4. Radiation Injury Drugs Industry Restraints Table 5. Global Radiation Injury Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiation Injury Drugs Revenue Share by Company (2021-2026) Table 7. Global Radiation Injury Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Radiation Injury Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Radiation Injury Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Radiation Injury Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Radiation Injury Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Radiation Injury Drugs Company, Product Type & Application Table 13. Global Radiation Injury Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Radiation Injury Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of DG-3 Table 18. Significant Companies of Des-Asp Angiotensin 1 Table 19. Significant Companies of C-2E5 Table 20. Significant Companies of C-2E2 Table 21. Significant Companies of BMX-001 Table 22. Significant Companies of Aerosurf Table 23. Significant Companies of Others Table 24. Global Radiation Injury Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Radiation Injury Drugs Sales Volume by Type (2021-2026) & (K Units) Table 26. Global Radiation Injury Drugs Sales Volume by Type (2027-2032) & (K Units) Table 27. Global Radiation Injury Drugs Sales Volume Share by Type (2021-2026) Table 28. Global Radiation Injury Drugs Sales Volume Share by Type (2027-2032) Table 29. Global Radiation Injury Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Radiation Injury Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Radiation Injury Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Radiation Injury Drugs Sales Value Share by Type (2021-2026) Table 33. Global Radiation Injury Drugs Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Hospital Table 35. Significant Companies of Clinic Table 36. Significant Companies of ASCs Table 37. Significant Companies of Others Table 38. Global Radiation Injury Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Radiation Injury Drugs Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Radiation Injury Drugs Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Radiation Injury Drugs Sales Volume Share by Application (2021-2026) Table 42. Global Radiation Injury Drugs Sales Volume Share by Application (2027-2032) Table 43. Global Radiation Injury Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Radiation Injury Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Radiation Injury Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Radiation Injury Drugs Sales Value Share by Application (2021-2026) Table 47. Global Radiation Injury Drugs Sales Value Share by Application (2027-2032) Table 48. Global Radiation Injury Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Radiation Injury Drugs Sales by Region (2021-2026) & (K Units) Table 50. Global Radiation Injury Drugs Sales Market Share by Region (2021-2026) Table 51. Global Radiation Injury Drugs Sales by Region (2027-2032) & (K Units) Table 52. Global Radiation Injury Drugs Sales Market Share by Region (2027-2032) Table 53. Global Radiation Injury Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Radiation Injury Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Radiation Injury Drugs Sales Value Share by Region (2021-2026) Table 56. Global Radiation Injury Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Radiation Injury Drugs Sales Value Share by Region (2027-2032) Table 58. Global Radiation Injury Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Radiation Injury Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Radiation Injury Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Radiation Injury Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Radiation Injury Drugs Sales by Country (2021-2026) & (K Units) Table 63. Global Radiation Injury Drugs Sales Market Share by Country (2021-2026) Table 64. Global Radiation Injury Drugs Sales by Country (2027-2032) & (K Units) Table 65. Global Radiation Injury Drugs Sales Market Share by Country (2027-2032) Table 66. Global Radiation Injury Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Radiation Injury Drugs Sales Value Market Share by Country (2021-2026) Table 68. Global Radiation Injury Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Radiation Injury Drugs Sales Value Market Share by Country (2027-2032) Table 70. Windtree Therapeutics Inc Company Information Table 71. Windtree Therapeutics Inc Business Overview Table 72. Windtree Therapeutics Inc Radiation Injury Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Windtree Therapeutics Inc Radiation Injury Drugs Product Portfolio Table 74. Windtree Therapeutics Inc Recent Development Table 75. Tonix Pharmaceuticals Holding Corp Company Information Table 76. Tonix Pharmaceuticals Holding Corp Business Overview Table 77. Tonix Pharmaceuticals Holding Corp Radiation Injury Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Tonix Pharmaceuticals Holding Corp Radiation Injury Drugs Product Portfolio Table 79. Tonix Pharmaceuticals Holding Corp Recent Development Table 80. Synedgen Inc Company Information Table 81. Synedgen Inc Business Overview Table 82. Synedgen Inc Radiation Injury Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Synedgen Inc Radiation Injury Drugs Product Portfolio Table 84. Synedgen Inc Recent Development Table 85. PharmaIN Corp Company Information Table 86. PharmaIN Corp Business Overview Table 87. PharmaIN Corp Radiation Injury Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. PharmaIN Corp Radiation Injury Drugs Product Portfolio Table 89. PharmaIN Corp Recent Development Table 90. FirstString Research Inc Company Information Table 91. FirstString Research Inc Business Overview Table 92. FirstString Research Inc Radiation Injury Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. FirstString Research Inc Radiation Injury Drugs Product Portfolio Table 94. FirstString Research Inc Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Radiation Injury Drugs Distributors List Table 98. Radiation Injury Drugs Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Radiation Injury Drugs Product Image Figure 2. Global Radiation Injury Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiation Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Radiation Injury Drugs Sales (2021-2032) & (K Units) Figure 5. Global Radiation Injury Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Radiation Injury Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. DG-3 Image Figure 10. Des-Asp Angiotensin 1 Image Figure 11. C-2E5 Image Figure 12. C-2E2 Image Figure 13. BMX-001 Image Figure 14. Aerosurf Image Figure 15. Others Image Figure 16. Global Radiation Injury Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Radiation Injury Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Radiation Injury Drugs Sales Volume Share by Type (2021-2032) Figure 19. Global Radiation Injury Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Radiation Injury Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Radiation Injury Drugs Sales Value Share by Type (2021-2032) Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. ASCs Image Figure 25. Others Image Figure 26. Global Radiation Injury Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Radiation Injury Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Radiation Injury Drugs Sales Volume Share by Application (2021-2032) Figure 29. Global Radiation Injury Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Radiation Injury Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Radiation Injury Drugs Sales Value Share by Application (2021-2032) Figure 32. Global Radiation Injury Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Radiation Injury Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Radiation Injury Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Radiation Injury Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Radiation Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. North America Radiation Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Radiation Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Radiation Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Radiation Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Radiation Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Radiation Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. South America Radiation Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Radiation Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Radiation Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Radiation Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Radiation Injury Drugs Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Radiation Injury Drugs Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • DG-3
  • Des-Asp Angiotensin 1
  • C-2E5
  • C-2E2
  • BMX-001
  • Aerosurf
  • Others
Applications
  • Hospital
  • Clinic
  • ASCs
  • Others
Companies covered
  • Windtree Therapeutics Inc
  • Tonix Pharmaceuticals Holding Corp
  • Synedgen Inc
  • PharmaIN Corp
  • FirstString Research Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Radiation Injury Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Radiation Injury Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Radiation Injury Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Radiation Injury Drugs Market Dynamics
  1. 2.1 Radiation Injury Drugs Industry Trends
  2. 2.2 Radiation Injury Drugs Industry Drivers
  3. 2.3 Radiation Injury Drugs Industry Opportunities and Challenges
  4. 2.4 Radiation Injury Drugs Industry Restraints
3 Radiation Injury Drugs Market by Company
  1. 3.1 Global Radiation Injury Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Radiation Injury Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Radiation Injury Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Radiation Injury Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Radiation Injury Drugs Company Ranking (2024-2026)
  6. 3.6 Global Radiation Injury Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Radiation Injury Drugs Company Product Type and Application
  8. 3.8 Global Radiation Injury Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Radiation Injury Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Radiation Injury Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Radiation Injury Drugs Market by Type
  1. 4.1 Radiation Injury Drugs Type Introduction
  2. 4.1.1 DG-3
  3. 4.1.2 Des-Asp Angiotensin 1
  4. 4.1.3 C-2E5
  5. 4.1.4 C-2E2
  6. 4.1.5 BMX-001
  7. 4.1.6 Aerosurf
  8. 4.1.7 Others
  9. 4.2 Global Radiation Injury Drugs Sales Volume by Type
  10. 4.2.1 Global Radiation Injury Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Radiation Injury Drugs Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Radiation Injury Drugs Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Radiation Injury Drugs Sales Value by Type
  14. 4.3.1 Global Radiation Injury Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Radiation Injury Drugs Sales Value by Type (2021-2032)
  16. 4.3.3 Global Radiation Injury Drugs Sales Value Share by Type (2021-2032)
5 Radiation Injury Drugs Market by Application
  1. 5.1 Radiation Injury Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 ASCs
  5. 5.1.4 Others
  6. 5.2 Global Radiation Injury Drugs Sales Volume by Application
  7. 5.2.1 Global Radiation Injury Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Radiation Injury Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Radiation Injury Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Radiation Injury Drugs Sales Value by Application
  11. 5.3.1 Global Radiation Injury Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Radiation Injury Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Radiation Injury Drugs Sales Value Share by Application (2021-2032)
6 Radiation Injury Drugs Regional Sales and Value Analysis
  1. 6.1 Global Radiation Injury Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiation Injury Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Radiation Injury Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Radiation Injury Drugs Sales by Region (2027-2032)
  5. 6.3 Global Radiation Injury Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Radiation Injury Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Radiation Injury Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Radiation Injury Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Radiation Injury Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Radiation Injury Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Radiation Injury Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Radiation Injury Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Radiation Injury Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Radiation Injury Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Radiation Injury Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Radiation Injury Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Radiation Injury Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Radiation Injury Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Radiation Injury Drugs Sales Value Share by Country, 2025 VS 2032
7 Radiation Injury Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Radiation Injury Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiation Injury Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Radiation Injury Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Radiation Injury Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Radiation Injury Drugs Sales by Country (2027-2032)
  6. 7.4 Global Radiation Injury Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Radiation Injury Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Radiation Injury Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Radiation Injury Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Radiation Injury Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Radiation Injury Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Windtree Therapeutics Inc
  2. 8.1.1 Windtree Therapeutics Inc Company Information
  3. 8.1.2 Windtree Therapeutics Inc Business Overview
  4. 8.1.3 Windtree Therapeutics Inc Radiation Injury Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Windtree Therapeutics Inc Radiation Injury Drugs Product Portfolio
  6. 8.1.5 Windtree Therapeutics Inc Recent Developments
  7. 8.2 Tonix Pharmaceuticals Holding Corp
  8. 8.2.1 Tonix Pharmaceuticals Holding Corp Company Information
  9. 8.2.2 Tonix Pharmaceuticals Holding Corp Business Overview
  10. 8.2.3 Tonix Pharmaceuticals Holding Corp Radiation Injury Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tonix Pharmaceuticals Holding Corp Radiation Injury Drugs Product Portfolio
  12. 8.2.5 Tonix Pharmaceuticals Holding Corp Recent Developments
  13. 8.3 Synedgen Inc
  14. 8.3.1 Synedgen Inc Company Information
  15. 8.3.2 Synedgen Inc Business Overview
  16. 8.3.3 Synedgen Inc Radiation Injury Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Synedgen Inc Radiation Injury Drugs Product Portfolio
  18. 8.3.5 Synedgen Inc Recent Developments
  19. 8.4 PharmaIN Corp
  20. 8.4.1 PharmaIN Corp Company Information
  21. 8.4.2 PharmaIN Corp Business Overview
  22. 8.4.3 PharmaIN Corp Radiation Injury Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 PharmaIN Corp Radiation Injury Drugs Product Portfolio
  24. 8.4.5 PharmaIN Corp Recent Developments
  25. 8.5 FirstString Research Inc
  26. 8.5.1 FirstString Research Inc Company Information
  27. 8.5.2 FirstString Research Inc Business Overview
  28. 8.5.3 FirstString Research Inc Radiation Injury Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 FirstString Research Inc Radiation Injury Drugs Product Portfolio
  30. 8.5.5 FirstString Research Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Radiation Injury Drugs Value Chain Analysis
  2. 9.1.1 Radiation Injury Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Radiation Injury Drugs Sales Mode & Process
  6. 9.2 Radiation Injury Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Radiation Injury Drugs Distributors
  9. 9.2.3 Radiation Injury Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst